124 related articles for article (PubMed ID: 19786086)
1. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis.
Kuroda Y; Saito M
Toxicol In Vitro; 2010 Mar; 24(2):661-8. PubMed ID: 19786086
[TBL] [Abstract][Full Text] [Related]
2. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
3. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
[TBL] [Abstract][Full Text] [Related]
4. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
5. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
[TBL] [Abstract][Full Text] [Related]
6. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
7. Hydrophilic interaction chromatography with a focus on the drug-phosphate interaction in drug screening to determine the phospholipidosis induction risk.
Okamoto H; Hamaguchi R; Kuroda Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Apr; 1051():33-40. PubMed ID: 28285021
[TBL] [Abstract][Full Text] [Related]
8. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
9. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.
Ploemen JP; Kelder J; Hafmans T; van de Sandt H; van Burgsteden JA; Saleminki PJ; van Esch E
Exp Toxicol Pathol; 2004 Mar; 55(5):347-55. PubMed ID: 15088636
[TBL] [Abstract][Full Text] [Related]
10. Types of interaction of amphiphilic drugs with phospholipid vesicles.
Joshi UM; Kodavanti PR; Coudert B; Dwyer TM; Mehendale HM
J Pharmacol Exp Ther; 1988 Jul; 246(1):150-7. PubMed ID: 3392651
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis.
Hirode M; Ono A; Miyagishima T; Nagao T; Ohno Y; Urushidani T
Toxicol Appl Pharmacol; 2008 Jun; 229(3):290-9. PubMed ID: 18355885
[TBL] [Abstract][Full Text] [Related]
12. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
13. Cationic amphiphilic drug-induced phospholipidosis.
Halliwell WH
Toxicol Pathol; 1997; 25(1):53-60. PubMed ID: 9061852
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis.
Joshi UM; Rao P; Kodavanti S; Lockard VG; Mehendale HM
Biochim Biophys Acta; 1989 Aug; 1004(3):309-20. PubMed ID: 2758025
[TBL] [Abstract][Full Text] [Related]
15. A role for lysosomal phospholipase A2 in drug induced phospholipidosis.
Abe A; Hiraoka M; Shayman JA
Drug Metab Lett; 2007 Jan; 1(1):49-53. PubMed ID: 19356018
[TBL] [Abstract][Full Text] [Related]
16. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
17. Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery.
Zhou L; Geraci G; Hess S; Yang L; Wang J; Argikar U
Anal Chem; 2011 Sep; 83(18):6980-7. PubMed ID: 21790130
[TBL] [Abstract][Full Text] [Related]
18. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Fischer H; Atzpodien EA; Csato M; Doessegger L; Lenz B; Schmitt G; Singer T
J Med Chem; 2012 Jan; 55(1):126-39. PubMed ID: 22122484
[TBL] [Abstract][Full Text] [Related]
19. Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect.
Pauluhn J
Toxicology; 2005 Feb; 207(1):59-72. PubMed ID: 15590122
[TBL] [Abstract][Full Text] [Related]
20. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals.
Jiang Z; Reilly J
J Pharm Biomed Anal; 2012 Mar; 61():184-90. PubMed ID: 22200505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
